Payment overview · 2025
General Payments
$1,064.39
53 reported records · 12 companies
Healthcare provider profile · identity verified
Kshama Keshava Bhat, MD
Allopathic & Osteopathic Physicians|Family Medicine · MILWAUKEE, WI · NPI 1255526190
Verified facts
What the public records show
CMS Open Payments records show Kshama Keshava Bhat, MD received $1,064.39 in general payments during 2025 across 53 reported records.
Novo Nordisk Inc accounted for 58.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Wegovy.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $621.65 | 58.4% | 29 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $151.27 | 14.2% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.36 | 4.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.75 | 3.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.05 | 3.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.03 | 3.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $32.83 | 3.1% | 2 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.72 | 2.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.40 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.24 | 1.5% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.91 | 1.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.18 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,064.39 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $364.25 | 14 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $51.36 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $41.54 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $40.35 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $38.05 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $37.03 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.27 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $32.83 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $32.83 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| BAQSIMI Normalized: baqsimi |
Drug | Amphastar Pharmaceuticals, Inc. | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $10.30 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 189 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
189 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 267 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 216 | 64 |
| Ozempic | Semaglutide | 189 | 34 |
| Losartan Potassium | Losartan Potassium | 150 | 41 |
| Lisinopril | Lisinopril | 135 | 41 |
| Furosemide | Furosemide | 128 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 123 | 40 |
| Omeprazole | Omeprazole | 117 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 116 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 34 |
| Metformin Hcl | Metformin Hcl | 91 | 30 |
| Montelukast Sodium | Montelukast Sodium | 87 | 27 |
| Famotidine | Famotidine | 81 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 18 |
| Linzess | Linaclotide | 71 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 21 |
| Gabapentin | Gabapentin | 69 | 21 |
| Potassium Chloride | Potassium Chloride | 69 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 68 | 22 |
| Carvedilol | Carvedilol | 66 | 17 |
| Clonazepam | Clonazepam | 66 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 17 |
| Azithromycin | Azithromycin | 59 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 11 |
| Alendronate Sodium | Alendronate Sodium | 55 | 16 |
| Tramadol Hcl | Tramadol Hcl | 52 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 14 |
| Fluconazole | Fluconazole | 50 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 13 |
| Allopurinol | Allopurinol | 46 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 33 |
| Alprazolam | Alprazolam | 39 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 32 |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Prednisone | Prednisone | 35 | 17 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 34 | 15 |
| Spironolactone | Spironolactone | 32 | 12 |
| Wegovy | Semaglutide | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Eliquis | Apixaban | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 21 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Simvastatin | Simvastatin | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Mupirocin | Mupirocin | 21 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 11 |
| Cephalexin | Cephalexin | 19 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,064.39 · 53 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, BAQSIMI, CAPVAXIVE, CONTRAVE, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, Kerendia, MOUNJARO, Ozempic, SHINGRIX, The Cologuard Plus Collection Kit, VAXNEUVANCE, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error